The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study.
John Neil Primrose
Consultant or Advisory Role - Merck
Stephen Falk
No relevant relationships to disclose
Meg Finch-Jones
No relevant relationships to disclose
Juan W. Valle
Honoraria - Merck
David Sherlock
No relevant relationships to disclose
Joanne Hornbuckle
No relevant relationships to disclose
James Gardner-Thorpe
No relevant relationships to disclose
David Smith
No relevant relationships to disclose
Charles Imber
No relevant relationships to disclose
Tamas Hickish
Research Funding - Sanofi
Brian Davidson
No relevant relationships to disclose
David Cunningham
Research Funding - Amgen; Celgene; Merck Serono; Novartis; Roche; Sanofi
Graeme John Poston
Consultant or Advisory Role - Merck; Sanofi
Tim Maughan
Consultant or Advisory Role - Merck
Myrrdyn Rees
No relevant relationships to disclose
Louise Stanton
No relevant relationships to disclose
Louisa Little
No relevant relationships to disclose
Megan Bowers
No relevant relationships to disclose
Wendy Wood
No relevant relationships to disclose
John A. Bridgewater
Consultant or Advisory Role - Merck Serono